Project Grant R37CA315608
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $510K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded Duke University $726,421 under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 19, 2026, to investigate epigenetic mechanisms of adaptive plasticity in glioblastoma. The research develops and validates methods for predicting cell state–specific vulnerabilities based on epigenetic data in glioblastoma tumors, characterizes adaptive plasticity–induced vulnerabilities during therapy using heterogeneous tumor models, and validates...
- The National Institutes of Health National Cancer Institute awarded the University of California, Los Angeles $404,972 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decode mechanisms behind durable immunotherapy responses in glioblastoma. The research uses spatial transcriptomics, high-plex immunofluorescence, and single-cell sequencing to map immune architecture in tumor samples from long-term survivors treated with autologous tumor lysate-pulsed dendritic cell...
- The National Institutes of Health National Cancer Institute awarded The Washington University $645,185 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to develop and test a combination immunotherapy approach for glioblastoma. The recipient will conduct research on an "expand and pull" strategy combining long-acting interleukin-7 (IL-7) with oncolytic virus therapy to expand peripheral CD8+ T cells and recruit them into the glioblastoma tumor microenvironment....
- The National Cancer Institute awarded Northwestern University $496,357 under the Cancer Treatment Research program (CFDA 93.395) on April 17, 2026, to investigate mechanisms of immunosuppression in glioblastoma and develop therapeutic interventions targeting tumor-associated macrophage polarization. The research centers on the peri-necrotic niche within IDH-wildtype glioblastoma tumors, where hypoxic glioma cells and immunosuppressive tumor-associated macrophages aggregate in spatial...
- The National Cancer Institute awarded The Ohio State University $567,754 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on immunotherapy for glioblastoma by targeting an immunoregulatory neuropeptide. The research addresses glioblastoma (GBM), the most lethal primary brain tumor, which exhibits remarkable resistance to immunotherapy due to CD8 T cell exclusion and dysfunction driven by immunosuppressive myeloid cells, particularly tumor-associated...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $2.554 million on March 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop biomaterial-enhanced CAR-T and CAR natural killer cell therapies for glioblastoma treatment. The award funds a comprehensive research program structured around three interconnected research projects. The first project integrates CAR T cell and CAR natural killer T cell therapy with an acetalated dextran...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $702,132 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics screening aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The research program will expose glioblastoma neurosphere models to 3,792 small...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $470,694 on July 2, 2026, to develop a nano electrospun polymeric biomaterial scaffold for glioblastoma interstitial immunotherapy under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The research focuses on engineering acetalated dextran (ACE-DEX), a tunable polymer that can be electrospun into nanofiber scaffolds, to deliver a toll-like receptor 7 & 8 agonist for local immunotherapy at...
- The National Cancer Institute awarded Duke University $1.882 million under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, to integrate genome-wide association study data with single-cell omics to reveal the cellular effectors of glioblastoma predisposition. Work will be performed in Durham, North Carolina, with a completion date of August 31, 2029. The Cancer Biology Research program funds fundamental information on the cause and nature of cancer, encompassing cancer...